Cibus (CBUS) AI Stock Analysis

• Market Cap: $74.65M
• Dividend Yield: N/A
• Average Volume (3M): 684.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.61
• Revenue Growth: 104.78%
• EPS Growth: 40.41%
• Country: US
• Employees: 157
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -1.34
• Shares Outstanding: 48,386,467
• 10 Day Avg. Volume: 766,518
• 30 Day Avg. Volume: 684,265
• PEG Ratio: <0.01
• Price to Book (P/B): 0.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.33
• Enterprise Value/Market Cap: 0.23
• Enterprise Value/Revenue: 1.05
• Enterprise Value/Gross Profit: 5.61
• Enterprise Value/Ebitda: -0.01
• 1Y Price Target: $21.17
• Price Target Upside: 1301.99% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 39 Underperform
• Price Target: $1.50 ▼(-0.66%Downside)

Cibus's overall stock score is primarily driven by its challenging financial performance, with significant net losses and high debt levels. Technical analysis further confirms bearish trends, and the company's current valuation is concerning due to a negative P/E ratio. While there are positive corporate developments, they do not outweigh the financial and technical weaknesses.

Positive Factors

Financial Performance

Cibus' revenues increased by 135% year-over-year, mainly through collaboration agreements and sales related to developing a palm oil alternative.

Product Development

The US FDA completed its Plant Biotechnology Consultation Program for the company’s altered lignin alfalfa trait for livestock feed, enabling the commercialization of the plant.

Regulatory Approvals

Cibus announced that its most recent HT2 trait iteration in Canola was deemed 'not regulated' by USDA-APHIS, increasing the company’s total number of traits designated as such to 17.

Negative Factors

Cash Flow

Cibus has sufficient cash reserves to finance its capital requirements through late third quarter of the next year.

Financial Loss

The company produced a net loss of ~$47M, widening over 300% y/y, primarily due to a significant goodwill impairment charge.

Market Expansion

The development in Ecuador could result in more inroads into the Latin American marketplace for the company.

Cibus Business Overview & Revenue Model

Company Description

Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.

How the Company Makes Money

Cibus generates revenue through the commercialization of its proprietary gene editing technologies, which are licensed to seed companies and agricultural producers. The company earns money by partnering with these entities to develop crops with enhanced traits, such as increased drought tolerance or pest resistance. These partnerships often involve milestone payments, royalties on sales of seeds and crops developed using Cibus technologies, and research and development collaborations. Additionally, Cibus may engage in strategic alliances to expand its technology applications and market reach, further contributing to its revenue streams.

Cibus Financial Statement Overview

Summary

Cibus is experiencing financial difficulties with persistent net losses and negative cash flows. While revenue has grown by 11.5%, high debt levels and negative profitability margins indicate a precarious financial position.

Income Statement

Cibus shows a pattern of increasing revenue in the TTM with a 11.5% growth from the previous annual period. However, the company continues to face significant challenges with profitability, as evidenced by a negative EBIT margin and net profit margin. The gross profit margin is positive, but the overall financial health is weakened by substantial net losses.

Balance Sheet

The company's balance sheet indicates a high debt-to-equity ratio, showing a heavy reliance on debt financing. The return on equity remains negative, reflecting ongoing net losses. However, the equity ratio is relatively stable, suggesting some level of balance sheet strength.

Cash Flow

Cibus has a negative free cash flow, which has deteriorated further in the TTM. The operating cash flow to net income ratio is negative, indicating operational challenges in generating cash. While financing activities provide some cash inflow, the continuous negative free cash flow poses a risk to financial sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.75M	4.26M	1.82M	157.00K	25.99M	23.85M
Gross Profit	3.02M	4.26M	1.42M	-1.38M	-2.57M	-11.28M
EBITDA	-264.21M	-241.63M	-314.58M	-15.21M	-25.43M	-41.53M
Net Income	-274.84M	-251.39M	-267.63M	-16.89M	-29.20M	-44.84M
Balance Sheet
Total Assets	335.05M	350.07M	544.41M	22.42M	37.19M	63.33M
Cash, Cash Equivalents and Short-Term Investments	23.59M	14.43M	32.70M	3.43M	13.82M	29.00M
Total Debt	35.65M	36.29M	24.62M	13.54M	17.88M	19.76M
Total Liabilities	261.09M	252.24M	206.12M	15.19M	23.06M	26.45M
Stockholders Equity	70.27M	92.16M	293.47M	7.23M	14.13M	36.88M
Cash Flow
Free Cash Flow	-82.04M	-58.85M	-50.53M	-20.88M	-19.31M	-45.46M
Operating Cash Flow	-80.78M	-58.04M	-46.21M	-19.36M	-18.81M	-43.67M
Investing Cash Flow	-1.26M	-808.00K	55.06M	-1.52M	11.20M	-13.48M
Financing Cash Flow	56.35M	40.60M	20.32M	9.99M	3.74M	15.41M

Cibus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Negative. The current price of 1.51 is below the 20-day moving average (MA) of 1.58, below the 50-day MA of 2.11, and below the 200-day MA of 2.83, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 40.58 is Neutral, neither overbought nor oversold. The STOCH value of 27.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CBUS.

Cibus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MGX	52 Neutral	$56.63M	―	-31.93%	―	-4.22%	18.67%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
AVTX	47 Neutral	$52.41M	―	678.24%	―	-69.59%	―
GANX	46 Neutral	$47.01M	―	-290.21%	―	-100.00%	44.28%
CBUS	39 Underperform	$74.65M	―	-157.73%	―	104.78%	40.41%
INZY	37 Underperform	$258.25M	―	-141.69%	―	―	-17.06%

Cibus Corporate Events

Cibus Announces Public Offering of Common Stock

On June 5, 2025, Cibus, Inc. entered into Securities Purchase Agreements with various investors, including its Board Chairman, as part of a public offering of 15,714,285 shares of Class A Common Stock. The offering, registered with the SEC, aims to raise funds for developing weed management traits in rice and other corporate purposes. The company has placed restrictions on stock transactions for 60 days post-offering. Additionally, Cibus engaged A.G.P./Alliance Global Partners as the sole placement agent, agreeing to a fee structure based on the proceeds from the sale of shares, with certain exclusions for the Board Chairman’s purchases.

The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus Announces Strategic Realignment to Streamline Operations

Cibus, Inc. announced a strategic realignment to streamline operations, focusing on the commercial advancement of its weed management traits in rice and partner-funded sustainable ingredient programs. The company aims to reduce its annual net cash burn to $30 million by 2026 through cost-cutting measures, including rationalizing human capital and non-core facilities. Recent regulatory approvals in the U.S., Ecuador, and India support the company’s gene editing technologies, potentially enhancing its market positioning and facilitating future partnerships. Cibus plans to launch its rice traits commercially in Latin America by 2027-2028, with further expansion planned in the U.S. and Asia.

The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus Stockholders Approve 2025 Employee Stock Plan

On May 22, 2025, Cibus, Inc.’s stockholders approved the adoption of the 2025 Employee Stock Purchase Plan (ESPP) during the company’s annual meeting. The plan, which was previously approved by the Board of Directors, includes the reservation of 326,384 shares of Class A common stock, with potential for annual increases. This approval marks a significant step in enhancing employee engagement and investment in the company, potentially impacting Cibus’s market position and stakeholder interests.

The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus Approves Key Measures at Annual Meeting

On May 22, 2025, Cibus, Inc. held its 2025 Annual Meeting of Stockholders where 64.94% of shares were represented. During the meeting, seven directors were elected, executive compensation was approved, BDO USA, P.C.’s appointment was ratified, and the 2025 Employee Stock Purchase Plan was approved. Additionally, the issuance and repricing of certain warrants, including those held by Rory Riggs, were approved, potentially leading to a change of control under Nasdaq rules.

The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.